merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>offers an FDA‑approved, safer alternative at a relatively low price</answer>
<question_number>2</question_number>
<answer>direct-to-patient sales via LillyDirect with home delivery and lower pricing, bypassing third‑party telehealth compounders</answer>
<question_number>3</question_number>
<answer>lack of FDA oversight—uncertain safety, quality, and effectiveness</answer>
<question_number>4</question_number>
<answer>to win back users of compounded tirzepatide by undercutting them with a cheaper FDA‑approved option, even if some pen users switch</answer>
<question_number>5</question_number>
<answer>being on the FDA shortage list permits compounding; removal would leave “no space for mass compounders”</answer>
<question_number>6</question_number>
<answer>direct-to-consumer pricing by cutting out intermediaries to offer “transparent pricing”</answer>
<question_number>7</question_number>
<answer>older Medicare patients may self-pay for vials, exposing them to risks like muscle loss and fractures</answer>
<question_number>8</question_number>
<answer>positions Lilly’s vials as a safer, FDA‑approved option, making compounded versions seem riskier</answer>
<question_number>9</question_number>
<answer>FDA “in shortage” listing</answer>
<question_number>10</question_number>
<answer>lower pricing on vials to undercut compounders</answer>